SEATTLE, Nov. 22, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV.OB - News), is pleased to announce that Mark Reddish has joined its Management Team as Vice President of Product Development. Mark was formerly Vice President of Product Development and Principal Investigator, Biodefense at ID Biomedical, Bothell, WA, prior to the acquisition of the company by Glaxo SmithKline for $1.6 billion. At Biomira Inc, (renamed Oncothyreon) he was responsible for preclinical development of their cancer vaccines program where he led the early research and clinical development of Stimuvax, which is currently in late Stage 3 clinical trials under a partnership with Merck KGa.
